GILDGILDHealthcare · Drug Manufacturers - General

GILD Stock Forecast: Gilead Sciences, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$166
−0.04% on the day

The 28 Wall Street analysts covering Gilead Sciences, Inc. hold a median 12-month price target of $178 — +6.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 89 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$206.6B
Ticker Nerd rank
89/ 100
Median analyst target
$178
Analysts covering
28
Revenue$7.8B+10.2% y/y
Operating income$2.5B
Net income−$10.5B
Free cash flow$3.4B
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.0%
1M
+6.4%
YTD
+38.0%
1Y
+36.4%
From 52W high
−4.6%
From 52W low
+43.2%
$116
$174
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Gilead Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
89/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
100
Value
99
Accruals
98
Quality
92
Momentum
86
Revisions
54
Growth
51
Issuance
51

Volatility (100): The share price has been relatively steady.

Issuance (51): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

GILD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GILD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$120$140$160$180$200Jan 26Apr 26Jul 26Oct 26GILDHigh $200Median $178Low $131

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says28 analysts
22
Buy
5
Hold
1
Sell
$131
Low
$178
Median
$200
High

The green dot is the last close — the median target sits +6.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 17 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
16 Nov 2026BarclaysMaintainsEqual-Weight$145 → $160
31 Oct 2026UBSMaintainsBuy—
30 Oct 2026Cantor FitzgeraldMaintainsOverweight$155 → $175
30 Oct 2026CitigroupMaintainsBuy$165 → $188
30 Oct 2026JP MorganMaintainsOverweight$170 → $190
30 Oct 2026Morgan StanleyMaintainsOverweight$163 → $183
30 Oct 2026NeedhamMaintainsBuy$170 → $200
30 Oct 2026RBC CapitalMaintainsSector Perform$126 → $131
30 Oct 2026ScotiabankMaintainsSector Outperform$177 → $200
30 Oct 2026TD CowenMaintainsBuy$160 → $175
30 Oct 2026Truist SecuritiesMaintainsBuy$158 → $181
30 Oct 2026UBSMaintainsBuy$175 → $195
30 Oct 2026Wells FargoMaintainsOverweight$165 → $190
20 Oct 2026B of A SecuritiesMaintainsBuy$168 → $172
8 Oct 2026Cantor FitzgeraldReiteratesOverweight$155
8 Oct 2026RBC CapitalMaintainsSector Perform$123 → $126
7 Oct 2026JP MorganMaintainsOverweight$160 → $170
7 Oct 2026Morgan StanleyMaintainsOverweight$165 → $163
7 Oct 2026Truist SecuritiesMaintainsBuy$150 → $158
10 Sept 2026HSBCMaintainsBuy$155 → $175

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for GILD.

Market Radar

This page is one stock. Monday covers all of them.

GILD appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

GILD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Gilead Sciences, Inc. returned +36.4% against +6.9% for the S&P 500, dividends included.

GILD vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130140Jan 26Apr 26Jul 26Oct 26GILDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

GILD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
23
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
6.8×

Cheaper than 16% of US stocks

Price / book
16.1×

Cheaper than 4% of US stocks

EV / EBITDA
15.3×

Cheaper than 32% of US stocks

Growth & margins
Revenue growth (YoY)
6.8%

Higher than 46% of US stocks

Earnings growth (YoY)
—
Gross margin
79.8%

Higher than 90% of US stocks

Operating margin
38.2%

Higher than 92% of US stocks

Net margin
−12.5%

Higher than 19% of US stocks

Returns & dividend
Return on equity
−22.4%

Higher than 31% of US stocks

Return on assets
13.5%

Higher than 96% of US stocks

Dividend yield
1.9%

Higher than 41% of US dividend payers

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Gilead Sciences, Inc. has a market value of $206.6B and an enterprise value of $224.7B.

  • Revenue in the twelve months to 30 June 2026: $30.5B. The latest quarter grew 10.2% year on year.

  • Net income over the same four quarters: −$3.2B, a −10.6% net margin.

  • Diluted earnings per share, trailing twelve months: −$2.67.

  • Free cash flow in the twelve months to 30 June 2026: $12.9B.

  • Gilead Sciences, Inc. spent $1.4B on share buybacks and $4.1B on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 1.2B.

  • forward P/E: 16.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 1.94%.

  • Gilead Sciences, Inc. employs 17,000 people — $1.8M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

GILD and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - General
CompanyMarket capTKN rank
GILDGilead Sciences, Inc.$206.6B89
AMGNAmgen, Inc.$234.8B95
PFEPfizer Inc.$155.8B91
MRKMerck & Co., Inc.$331.9B86
BMYBristol Myers Squibb Co.$119.7B94
ABBVAbbVie, Inc.$505.7B90
JNJJohnson & Johnson$651.8B86

Take a look at GILD’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Gilead Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about GILD

What is the GILD stock price forecast for 2026-2027?

The 28 Wall Street analysts covering Gilead Sciences, Inc. have a median 12-month price target of $178, with estimates ranging from $131 to $200. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GILD stock a buy right now?

Of the 28 analysts covering Gilead Sciences, Inc., 22 rate it a Buy, 5 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Gilead Sciences, Inc. 89 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GILD?

As at 21 Nov 2026, Gilead Sciences, Inc. ranks 89 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (100 of 100).

Will GILD stock go up?

No one can know that. What the data says: the median 12-month target from 28 analysts implies +6.9% from the last close, and Ticker Nerd's factor model ranks Gilead Sciences, Inc. 89 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GILD stock forecast for 2030?

No analyst covering Gilead Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GILD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $131 to $200 over the next 12 months.

How has GILD stock performed over the past year?

Gilead Sciences, Inc. returned +36.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Gilead Sciences, Inc. do?

Gilead Sciences Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for serious and life-threatening diseases. Its current business centers on virology, oncology, and inflammation, with a particularly strong position in HIV treatment and a broader portfolio that also addresses liver disease, respiratory conditions, cardiovascular disease, and cancer.

Company

About Gilead Sciences, Inc.

Gilead Sciences Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for serious and life-threatening diseases. Its current business centers on virology, oncology, and inflammation, with a particularly strong position in HIV treatment and a broader portfolio that also addresses liver disease, respiratory conditions, cardiovascular disease, and cancer. Gilead Sciences Inc. markets established therapies and newer medicines aimed at unmet medical needs, supported by ongoing research and clinical programs across multiple therapeutic areas. The company also works with partnerships and access programs that help expand the reach of its medicines in global markets. Headquartered in Foster City, California, Gilead Sciences Inc. operates as an important healthcare innovator with products and services that serve patients, clinicians, and health systems worldwide.

CEO Mr. Daniel Patrick O'Day · 17,000 employees · United States · https://www.gilead.com